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Summary
A family-history cancer survey was conducted on 5,486
men who underwent a radical prostatectomy, for clini-
cally localized prostate cancer, in the Department of
Urology at the Mayo Clinic during 1966–95; 4,288 men
responded to the survey. Complex segregation analysis
was performed to assess the genetic basis of age at di-
agnosis and the familial clustering of prostate cancer.
For the total group, no single-gene model of inheritance
clearly explained familial clustering of disease, which
could be partly explained by lack of Hardy-Weinberg
equilibrium, with an excess of homozygotes. After ac-
counting for deviations from Hardy-Weinberg equilib-
rium, the best-fitting model that explained the familial
aggregation and age at diagnosis was a rare autosomal
dominant susceptibility gene, and this model fitted best
when probands were diagnosed at !60 years of age. The
model predicts that the frequency of the susceptibility
gene in the population is .006 and that the risk of pros-
tate cancer by age 85 years is 89% among carriers of
the gene and 3% among noncarriers. A strength of our
study is its large size, such that genetic models could be
fitted within strata defined by the age of the proband.
Although the autosomal dominant model was consis-
tently the best model, the parameter estimates differed
somewhat ( ) across the different age groups, sug-P  .03
gesting genetic heterogeneity. Additional evidence that
the hereditary basis of prostate cancer is likely to be
genetically complex was provided by the following: (1)
there was a significantly elevated age-adjusted risk of
prostate cancer among brothers of probands, compared
with their fathers (relative risk 1.5 [95% confidence in-
terval 1.4–1.7]); (2) the autosomal dominant model pre-
dicted an excess of homozygotes, over that predicted by
Hardy-Weinberg equilibrium; and (3) the model-pre-
dicted risk of prostate cancer among relatives was in-
adequate when probands were diagnosed at age x70
years.
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Introduction
Prostate cancer is the second most common malignant
cancer among men living in the United States, after skin
cancer. It is estimated that in 1997 ∼334,500 new pros-
tate cancer cases and ∼41,800 prostate cancer–related
deaths occurred in the United States (Parker et al. 1997)
and that a man has a chance of developing prostate15
cancer during his lifetime (Feuer 1997). Age is the pri-
mary risk factor, with incidence per 100,000 increasing
from 34 to 150 to 440 for U.S. Caucasian men ages 60,
70, and 80 years, respectively (Kosary et al. 1995). Cul-
tural and ethnic background may also have an etiologic
role, since there is a large variation in age-adjusted in-
cidence in different racial/ethnic groups throughout the
world, with the highest rates in U.S. African American
men, followed by U.S. Caucasian men, and with the
lowest rates among men in China and Japan (Muir et
al. 1987). Although some of these population differences
may be attributable to differences in diet and life style,
there is strong evidence that genetic alterations, both
somatic and heritable, play a major role in prostate can-
cer etiology.
A large number of studies have reported that male
first-degree relatives (father, sons, and brothers) of an
affected man are two to three times more likely to de-
velop prostate cancer, compared with men in the general
population (Woolf 1960; Cannon et al. 1982; Meikle
and Stanish 1982; Carter et al. 1990; Steinberg et al.
1990; Spitz et al. 1991; Goldgar et al. 1994; Whittemore
et al. 1995). A recent population-based case-control
study reported an odds ratio of 2.5, after adjustment for
age and ethnicity. Of most interest, however, is that this
odds ratio did not significantly differ across the three
U.S. and Canadian ethnic groups—African Americans,
Caucasians, and Asian Americans (Whittemore et al.
1995)—despite the large difference in incidence among
these ethnic groups. When there are multiple affected
men in a family, the risk to the remaining men increases
dramatically (Steinberg et al. 1990). A large twin study
in Sweden reported the heritability of prostate cancer to
be 33%–36% (Ahlbom et al. 1997).
To determine whether the familial clustering of pros-
tate cancer was consistent with Mendelian inheritance,
Carter et al. (1992) performed complex segregation
analyses on 691 families ascertained through probands
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undergoing radical prostatectomy for primary clinically
localized prostate cancer. The model that best fitted their
data was segregation of a rare autosomal dominant pros-
tate cancer–susceptibility gene; the estimated frequency
of the high-risk allele was 0.3%, and the estimated cu-
mulative risk of prostate cancer by age 85 years was
88% for carriers, versus 5% for noncarriers. A second
study employing complex segregation analysis of pros-
tate cancer recently has reported results on a population-
based sample of 2,857 Swedish nuclear families in which
the father was diagnosed during 1959–63 (Gro¨nberg et
al. 1997a). This study confirmed that autosomal dom-
inance best fitted the familial clustering of prostate can-
cer, but with a higher frequency of the susceptibility al-
lele (1.67%) and a lower lifetime penetrance (63%).
The limitations of the study by Carter et al. (1992)
are as follows: (1) the probands were primarily Cau-
casians (96%), which limited assessment of genetic het-
erogeneity across different ethnic groups; (2) the pro-
bands tended to be young (mean age at onset was 59.3
years, versus 73.5 years as the median age at diagnosis
among U.S. Caucasian men), so that there was limited
power to assess heterogeneity of autosomal dominant
Mendelian transmission across different age groups,
with a scarcity of men with later-onset disease; and (3)
the study was conducted during 1982–89—that is, for
the most part, before the 1987 introduction of serum
prostate-specific antigen (PSA) testing to the community
medical practice, making it difficult to extrapolate, to
current clinical practice, hereditary prostate cancer di-
agnosed without use of PSA. The recent dramatic in-
crease in prostate cancer incidence may be partly ex-
plained by the increased use of serum PSA testing
(Jacobsen et al. 1995), leading to detection of early-stage
cancers.
Further support for a genetic basis of prostate cancer
is the finding of early age at onset and autosomal dom-
inant inheritance within some families (Carter et al.
1993), as well as recent reports of genetic linkage of the
disease, in ∼34% of high-risk families, to chromosomal
region 1q24-25 (Smith et al. 1996; Cooney et al. 1997),
although this linkage finding has been difficult to repro-
duce consistently (McIndoe et al. 1997). Despite this
evidence of autosomal dominant inheritance, others
have reported findings that prostate cancer may have an
X-linked or recessive genetic component (Monroe et al.
1995). The purposes of the present study were to de-
termine whether results from complex segregation anal-
yses, particularly Mendelian autosomal dominant in-
heritance, could be reproduced in an independent cohort
of families and to assess heterogeneity due to age at
diagnosis of the proband.
Methods
All men undergoing radical prostatectomy for clini-
cally localized prostate cancer, in the Department of
Urology at the Mayo Clinic (Rochester, MN), are reg-
istered in our database, which began to prospectively
register men in 1987; cases from 1966–86 were retro-
spectively included. This cohort represents consecutive
pathologically confirmed prostate cancer cases, without
any selection other than that they were treated by a
radical prostatectomy at the Mayo Clinic. A survey re-
garding family history of cancer and with detailed em-
phasis on prostate cancer, approved by our institutional
review board, was sent in March 1995 to all 5,486 men
who were registered in our database and alive at the
time of the mailing; 866 deceased men were excluded.
A second mailing was sent, in June 1995, to 1,434 men
who had failed to return the first survey. The survey
collected information on all sons, brothers, father,
grandfathers, uncles, and male cousins, with regard to
prostate cancer, and on any other cancers among other
relatives. Age at diagnosis of prostate cancer was deter-
mined for all first-degree male relatives, as were vital
status and either current age or age at death. Adoption
status was also determined, to confirm biologic rela-
tionships. Prostate cancer history has been found to be
accurately reported for first-degree relatives and to be
underreported among more-distant relatives (Steinberg
et al. 1990), which is similar to findings for other types
of cancers (Bondy et al. 1994; Love et al. 1985). Because
of these prior reliability studies, we did not validate fam-
ily histories by medical-record review of relatives but,
instead, restricted complex segregation analyses to first-
degree relatives. However, all probands were treated at
the Mayo Clinic and had thorough medical examina-
tions. If a proband reported that he was adopted, then
only his sons were included in the segregation analyses.
Complex segregation analyses were performed by use
of genetic regressive models (Bonney 1986,) as imple-
mented in the SAGE (1994) computer package. Two
general factors, labeled “A” and “B,” were considered,
and these are assumed to give rise to three “types” of
people, labeled “AA,” “AB,” and “BB.” Under a genetic
model, these three types represent the genotypes for two
alleles, A, and B. For nongenetic models, these three
types are arbitrary, but they allow for population het-
erogeneity that is not necessarily due to genetic differ-
ences. Genetic contributions to the model are incorpo-
rated into the transmission parameters tAA, tAB, and tBB,
the probability that persons of a given type transmit the
A factor to their offspring (Elston and Stewart 1971;
Lalouel et al. 1983). Mendelian models of transmission
restrict the transmission parameters to ,t  1 t AA AB
, and , but more-general models provide the.5 t  0BB
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ability to test whether transmission fits Mendelian ex-
pectation. Furthermore, the population frequencies of
the three types of founding parents in the pedigrees are
represented by PAA, PAB, and PBB. These frequencies are
restricted to sum to 1, and, when Hardy-Weinberg equi-
librium (HWE) is assumed, these three frequencies de-
pend on the population frequency, q, of allele A
( , , and .2 2P  q P  2q[1 q] P  [1 q] )AA AB BB
The SAGE REGTL module was used to analyze age
at diagnosis while allowing for censored observations
(any male relative who did not have prostate cancer at
either his current age or the time of his death). Note
that age at diagnosis differs from age at onset, because
diagnosis depends on both the natural history of prostate
cancer and the methods used for diagnosis. Age at di-
agnosis, denoted as “x,” was assumed to be distributed
according to a logistic distribution (Bonney 1986),
which has the probability-distribution function P(x) 
and the cumulative distribution(b ax) (bax) 2[gae ]/[1 e ]
function . According to this(bax) (bax)F(x)  g[e ]/[1 e ]
model, the parameter a determines the rate of change
in the probability of prostate cancer as it depends on
age, and hence a determines the variability in the age at
diagnosis; we assumed that a is the same for all three
types of people. The parameter b influences the mean
age at diagnosis (mean b/a), and this parameter was
allowed to depend on the type of person (the genotype
of the person, for the genetic models). The parameter g
is the “susceptibility” parameter, the cumulative prob-
ability that one will have prostate cancer if he or she
lives long enough (Go et al. 1983); for all models, g was
fixed to be 0 for females. To correct for the method of
ascertainment, the likelihood for each pedigree was con-
ditioned on the proband’s disease status at his age at
diagnosis.
Complex segregation analyses were performed by fit-
ting four Mendelian models (dominant, recessive, co-
dominant, and additive) and three non-Mendelian mod-
els (a general unrestricted model; an environmental
model without generation effects, for which there is no
transmission of disease and for which the risk of prostate
cancer is assumed to be the same for both parent and
child generations [ ], although the three types weret  q
allowed to differ in disease probability, in order to allow
for population heterogeneity; and an environmental
model with generation effects, which is similar to an
environmental model without generation effects but al-
lows for generation differences [ ]). Hypotheses oft( q
disease transmission were tested by subtraction of twice
the loge likelihood of a restricted model from twice the
loge likelihood of the general unrestricted model. This
difference was compared with a x2 distribution with df
conservatively estimated as the difference in the number
of estimated parameters for the two models compared.
Comparison of participants versus nonparticipants, as
well as comparison of positive and negative family his-
tory, were made by use of x2 statistics for categorical
variables and by the Wilcoxon rank-sum test for age at
diagnosis. The cumulative distribution of prostate cancer
among first-degree relatives was estimated by Kaplan-
Meier methodology, accounting for censored observa-
tions. These distributions were correlated with charac-
teristics of the proband, by use of log-rank statistics, and
relative risks were estimated by the Cox proportional-
hazards model.
Results
Characteristics of Probands
Family-history questionnaires were sent to 5,486 men,
4,288 (78%) of whom were used for segregation anal-
yses. The reasons for exclusion of 1,198 men were as
follows: failure to return the questionnaire, return of
blank questionnaires, or refusal to participate, (n 
); proband deceased, without a proxy relative to1,134
complete the questionnaire ( ); being lost to fol-n  43
low-up ( ); and proband adopted and without an  4
son ( ). The clinical characteristics of the partici-n  17
pant and nonparticipant probands differed statistically,
for a number of factors (table 1), but the large sample
size allowed detection of some minor clinical differences.
The most striking difference was a higher rate of recur-
rence among nonparticipants, which may be due to less
willingness to participate by those men more ill because
of their disease (table 1). Among the 4,288 participants,
the clinical characteristics were similar for the 1,214 pro-
bands (28% of total) who had at least one first-degree
relative with prostate cancer and the 3,074 probands
(72% of total) without an affected first-degree relative
(table 2).
Correlation of Proband’s Characteristics with
Relative’s Age at Diagnosis
A total of 17,684 male relatives were reported on the
survey; they included 4,224 fathers (637 affected, 828
with unknown status, and 2,759 without prostate can-
cer), 6,789 brothers (863 affected, 604 of unknown
status, and 5,322 without prostate cancer), and 6,671
sons (17 affected, 156 of unknown status, and 6,498
without prostate cancer). Relatives were scored as hav-
ing an unknown status for prostate cancer if the proband
either indicated an unknown status for his relative or
left this response blank. The clinical characteristics of
each proband were analyzed to assess whether any were
correlated with the age at diagnosis among his relatives.
The age at diagnosis of the proband was trichotomized
by the cutoffs of 60 and 70 years, which approximately
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Table 1
Clinical Characteristics, by Survey Participation
CHARACTERISTIC
NO. (%) OF
P
Participants
( )n  4,288
Nonparticipants
( )n  1,198
TNM pathological stage:a
T0N0M0 30 (.7) 17 (1.4) .001
T1N0M0 101 (2.4) 21 (1.8)
T2N0M0 1,764 (41.4) 439 (37.1)
T34N0M0 1,814 (42.6) 517 (43.7)
TxN1M0 550 (12.9) 188 (15.9)
TxNxM1 0 (0) 1 (.1)
Unknown 29 15
Pathological grade:
1 82 (2.0) 24 (2.1) .61
2 2,304 (54.7) 637 (55.0)
3 1,677 (39.8) 447 (38.6)
4 150 (3.6) 50 (4.3)
Unknown 75 40
Recurrence:
Local 251 (5.9) 102 (8.5) .001
Systemic 153 (3.6) 91 (7.6) .001
Method at diagnosis:
Needle biopsy 3,890 (90.7) 1,096 (91.6) .34
Transurethral resection 288 (6.7) 78 (6.5)
Other 110 (2.6) 24 (1.8)
Age at diagnosis (years):
Median 65.6 66.4 .0005
Range 38–84 41–81
a T0  no evidence of primary tumor; T1  clinically undetectable
tumor; T2  tumor confined within prostate; T34  tumor extended
throughout prostatic capsule; Tx  tumor unable to be assessed; N0
 no regional lymph-node metastasis; N1metastasis in single lymph
node, X2 cm; Nx  regional lymph nodes unable to be assessed; M0
 no distinct metastatis; and M1  distant metastatis.
Table 2
Clinical Characteristics of Participating Probands With and
Without a Family History of Prostate Cancer among First-
Degree Relatives
CHARACTERISTIC
FAMILY-HISTORY STATUS
P
Negative
( )n  3,074
Positive
( )n  1,214
TNM pathological stage:a
T0N0M0 24 (.8) 6 (.5) .50
T1N0M0 70 (2.3) 31 (2.6)
T2N0M0 1,248 (40.9) 516 (42.8)
T34N0M0 1,304 (42.7) 510 (42.3)
TxN1M0 406 (13.3) 144 (11.9)
Unknown 22 7
Pathological grade:
1 61 (2.0) 21 (1.8) .16
2 1,623 (53.8) 681 (57.0)
3 1,218 (40.4) 459 (38.4)
4 116 (3.8) 34 (2.9)
Unknown 56 19
Recurrence:
Local 174 (5.7) 77 (6.3) .39
Systemic 113 (3.7) 40 (3.3) .54
Age at diagnosis (years):
Median 65.5 65.7 .95
Range 38-84 44-80
For definitions, see footnote to table 2.
correspond to the 20th and 80th percentiles of the dis-
tribution. Earlier age at diagnosis for the proband was
significantly correlated with an earlier age at diagnosis
among his first-degree relatives (fig. 1), but no other
clinical characteristics of the proband were correlated
with the distribution of the age at diagnosis among first-
degree relatives (table 3).
Segregation Analyses
The results from fitting segregation models when
HWE was assumed are presented in table 4. All envi-
ronmental and single-gene models were clearly rejected
as having adequate fits, relative to the general model.
Among the genetic models, the codominant model fitted
best, followed by the recessive model. To assess the lack
of model fit, all seven models were fit without restriction
to HWE (table 5). All models except the environmental
model without generation effects demonstrated signifi-
cant evidence against HWE (table 5). Although a sub-
stantial improvement in fit of the models was achieved,
with the best-fitting model as autosomal dominant, no
single model adequately explained the familial clustering
of prostate cancer.
To evaluate additional sources of heterogeneity, we
split the data into three subsets based on the age at
diagnosis of the proband (!60, 60–69, and x70 years)
and determined the best fit for the seven models, but not
assuming HWE. For each subset, the best-fitting model
was a rare autosomal dominant model (tables 6–8).
However, only for the subset of probands diagnosed at
age !60 years (table 6) did the autosomal dominant
model give an adequate fit, one that was much better
than that of the autosomal recessive model. For the later-
diagnosed probands (tables 7 and 8), the difference be-
tween dominant and recessive inheritance was not as
clear, even though the dominant model had a better fit;
the fit of the dominant model was not adequate for pro-
bands diagnosed at age 60–69 years (table 7) and was
marginally adequate for probands diagnosed at age x70
years (table 8). The estimated parameters for the dom-
inant models did not differ substantially across the three
age subsets, although a formal test of heterogeneity
across these subsets indicates that heterogeneity may ex-
ist ( , , ). As shown in figure2x  23.09 df  12 P  .03
2, the estimated age-dependent penetrances are similar
for the subset defined by proband age at diagnosis !60
years and for the subset defined by age at diagnosis
60–69 years, whereas the subset defined by proband age
at diagnosis x70 years tended to have a shift toward a
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Figure 1 Cumulative risk of prostate cancer among first-degree relatives, according to age at diagnosis of the proband. Cumulative risks
were estimated by nonparametric Kaplan-Meier methodology.
higher age at onset, both for carriers and for noncarriers.
This could be due to a higher frequency of sporadic cases
among the families with older probands.
To compare the predicted and observed cumulative
risks of prostate cancer among the fathers and brothers
of probands, the empirical cumulative risks were esti-
mated separately for fathers and brothers, for each of
the three strata defined by the probands’ age at diag-
nosis: !60 years, 60–69 years, and x70 years. These
cumulative risks are presented in figures 3–5. When ad-
justment is made for the age strata of the proband, the
risk to brothers was significantly greater than the risk
to fathers ( ), with a relative risk of 1.5 (95%P  .0001
confidence interval 1.4–1.7). Based on the parameters of
the autosomal dominant model that are given in table
5, the predicted cumulative risk to first-degree relatives
is also presented in figures 3–5. This predicted risk is
conditional on the age at diagnosis of the proband, as
defined by the strata. For probands diagnosed at age
!70 years, the predicted risks were between the empirical
risk for fathers and that for brothers (figs. 3 and 4),
suggesting that the model predictions were accurate.
However, for probands diagnosed at age x70 years, the
predicted risk grossly underestimated the observed risk
(fig. 5); this is mainly because it was assumed that the
age at diagnosis of the proband was 70–85 years for the
predicted risk, whereas our actual data had few pro-
bands diagnosed at age 180 years. If we restricted the
age of proband’s diagnosis to 70 years, then the pre-
dicted risk (not shown) agreed closely with the observed
risk shown in figure 5. Hence, the prediction error in
figure 5 represents extrapolation beyond the limits of
our data. In addition to use of the autosomal dominant
model, for the total data set (table 5), to predict risk to
relatives, each of the autosomal dominant models fitted
to the three age strata (tables 6–8) were used to predict
risk, but these predictions (not shown) were close to
those presented in figures 3–5.
For the autosomal dominant model, HWE was
strongly rejected for each age category (HWE models
not shown; ). The cause of deviation fromP ! .0001
HWE could be due to a stratified sample, such that allele
frequencies and disease prevalence differ across different
ethnic subgroups, and mating is not random between
the different ethnic subgroups. Our sample of probands
is neither population based nor homogeneous with re-
spect to ethnic background; rather, this sample is based
on referrals to the Mayo Clinic, a tertiary-care center,
with 3,826 probands representing 49 states of the United
States (excluding Hawaii) and Washington, DC, and
with 462 probands from outside the United States. A
total of 1,051 probands were Minnesota residents at the
time of their surgery; this subset is more homogeneous
with respect to ethnic background than is the total of
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Table 3
Correlation of Proband’s Characteristics with Age-Adjusted
Relative Risk of Prostate Cancer among First-Degree Relatives
Characteristic of Proband
No. of
Prostate
Cancers
Age-Adjusted
Relative Risk
(Standard Error)a P
Age at diagnosis (years):
!60 ( )n  3,062 279 1.74 (.08) .0001
60–69 ( )n  7,985 786 1.43 (.07)
x70 ( )n  3,163 282 1.0b
Pathological grade:
1 ( )n  231 28 1.0b .67
2 ( )n  7,618 754 .97 (.19)
3 ( )n  5,574 500 .92 (.19)
4 ( )n  526 42 .85 (.24)
Unknown ( )n  261 23 .77 (.28)
TNM pathological stage:c
T0N0M0 ( )n  108 4 .29 (.52) .12
T1N0M0 ( )n  369 40 1.0
b
T2N0M0 ( )n  5,827 566 .99 (.16)
T34N0M0 ( )n  5,873 558 1.01 (.16)
TxN1M0 ( )n  1,938 168 .89 (.18)
Unknown ( )n  95 11 1.08 (.34)
Ploidy status:
Diploid ( )n  8,394 795 1.0b .15
Aneuploid/tetraploid
( )n  3,781
357 .95 (.06)
Unknown ( )n  2,035 195 .86 (.08)
a Estimated by Cox proportional-hazards models.
b Reference group.
c For definitions, see footnote to table 1.
Table 4
Segregation Models Assuming HWE
MENDELIAN MODELS ENVIRONMENTAL MODELSa
GENERAL
MODELDominant Recessive Additive Codominant
Without Generation
Effects
With Generation
Effects
Parameter:
qA .0079 .3323 .0053 .3738 .3296* .2350 .0089
tAA 1.0
b 1.0b 1.0b 1.0b .3296* .3486* 1.0
tAB .5
b .5b .5b .5b .3296* .3486* .832
tBB .0
b .0b .0b .0b .3296* .3486* .0072
bAA 13.60 13.76 7.95 13.94 21.62 22.35 11.83
bAB 13.60 19.38 14.06 21.66 15.52 15.55 14.29
bBB 19.32 19.38 20.17 17.24 18.25 18.49 19.84
a .188 .190 .194 .193 .227 .228 .195
g 1.0 1.0 1.0 1.0 .479 .487 1.0
2n L 15,212.33 15,134.68 15,224.94 15,105.83 15,393.66 15,386.61 15,036.29
Model fit x2: 176.04 98.39 188.65 69.54 357.37 350.32
df 4 4 4 3 3 2
P !.0001 !.0001 !.0001 !.0001 !.0001 !.0001
After loge
transfor-
mation:c
Model fit x2: 189.70 117.37 195.96 105.37 400.45 381.16
P !.0001 !.0001 !.0001 !.0001 !.0001 !.0001
a Within each column, parameters denoted by an asterisk (*) are constrained to be equal.
b Parameter is fixed at value shown.
c Parameter estimates after loge transformation are not given.
all probands. For this subset of Minnesota residents, we
determined the best-fitting autosomal dominant models,
with and without the restriction of HWE; HWE was
rejected in this subset ( , ), and the2x  41.12 P ! .001
estimated parameters of the autosomal dominant model
were similar for Minnesota residents and the total group.
On the basis of this analysis, we could not find evidence
that ethnic heterogeneity was the potential major source
of deviation from HWE.
We have assumed that the age at diagnosis has a lo-
gistic probability distribution. Deviations from this as-
sumed distribution could cause a lack of fit of the mod-
els. To assess this, we attempted to simultaneously
estimate parameters that transform the age at diagnosis
to better fit a logistic distribution (Box-Cox transfor-
mation), along with the other genetic model parameters.
However, these attempts failed, because the numerical
algorithms did not converge. As an alternative, we trans-
formed the age at diagnosis by the natural logarithm
and fitted the seven models, with and without HWE.
These results (model-fit x2 values and P values) are pre-
sented at the bottoms of tables 4–8. Under HWE (table
4), the recessive model fitted somewhat better than the
dominant model, but all genetic models fitted poorly. In
contrast, when HWE was not required (tables 5–8), the
dominant model fitted substantially better than the re-
cessive model. We conclude that the lack of model fit is
primarily due to lack of HWE and not to the choice of
transformation for age. The restriction of HWE in our
data forces an underestimate of the frequency of ho-
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Table 5
Segregation Models Not Requiring HWE
MENDELIAN MODELS ENVIRONMENTAL MODELSa
GENERAL
MODELDominant Recessive Additive Codominant
Without Generation
Effects
With Generation
Effects
Parameter:
PAA .0036 .0659 .0450 .0038 .1709* .4773 .0024
PAB .0051 .1844 .1654 .0051 .3896
† .2699 .0698
PBB .9914 .7496 .7895 .9911 .4395
‡ .2527 .9064
tAA 1.0
b 1.0b 1.0b 1.0b .1709* .1839* 1.0
tAB .5
b .5b .5b .5b .3896† .1839* .841
tBB .0
b .0b .0b .0b .4395‡ .1839* .084
bAA 13.47 13.64 13.63 13.34 22.17 20.27 14.81
bAB 13.47 19.47 19.08 13.47 15.65 15.67 17.67
bBB 19.02 19.47 24.52 18.95 18.35 17.82 24.01
a .183 .188 .188 .183 .231 .237 .229
g 1.0 1.0 1.0 1.0 .504 .449 1.0
2n L 15,050.63 15,104.62 15,139.91 15,049.99 15,392.86 15,324.76 15,005.59
Model fit x2: 45.04 99.03 134.32 44.40 387.27 319.17
df 4 4 4 3 3 2
P !.0001 !.0001 !.0001 !.0001 !.0001 !.0001
Test of HWE
x2 (1 df):
161.70 30.06 85.03 55.84 .80 68.90 30.70
P !.0001 !.0001 !.0001 !.0001 .37 !.0001 !.0001
After loge
transfor-
mation:c
Model fit x2 44.73 113.29 205.85 43.19 401.55 341.23
P !.0001 !.0001 !.0001 !.0001 !.0001 !.0001
a Within each column, parameters with the same superscript symbol (*, †, or ‡) are constrained to be equal.
b Parameter is fixed at value shown.
c Parameter estimates after loge transformation are not given.
mozygous carriers (.0001 for HWE vs. .0036 for non-
HWE) and an overestimate of the frequency of hetero-
zygous carriers (.0157 for HWE vs. .0051 for non-
HWE). Also, without HWE (table 5), the general-model
transmission parameters and aret  .841 t  .084AB BB
both greater than they should be for a genetic model (.5
and 0, respectively), which can occur when there are
more affected offspring than are predicted by a genetic
model. We have examined outlier pedigrees (defined as
those having a large positive or negative additive con-
tribution to the model x2); yet, after removal of the 16
most extreme pedigrees, the general-model transmission
parameters were still larger than those for a genetic
model. Phenocopies, a mixture of dominant and reces-
sive effects, and secular trends in diagnosis could cause
the lack of fit of these genetic parameters.
Discussion
Our results support the existence of a rare autosomal
dominant prostate cancer–susceptibility gene that causes
an earlier age at onset among carriers. Support for this
finding is strongest among men diagnosed at age !60
years but is consistent among men diagnosed at older
ages. Our results tend to indicate that hereditary prostate
cancer is genetically complex and that a high rate of
phenocopies at older ages may be a reason why an au-
tosomal dominant model does not give a complete ex-
planation of the familial clustering of this disease. This
was particularly evidenced by the inadequacy of the best-
fitting model to predict the cumulative risk of prostate
cancer among first-degree relatives of men diagnosed at
age x70 years. Although, on the basis of the age at
diagnosis of the proband, there is some statistical evi-
dence that heterogeneity of the autosomal dominant
model may exist, the model parameters are similar for
probands diagnosed at age !70 years. Probands diag-
nosed at age x70 years may have a higher frequency
of nonhereditary prostate cancers among their relatives,
but the best-fitting model in this subset was autosomal
dominant, suggesting that the proband’s age at diagnosis
cannot be used to reliably discriminate hereditary from
nonhereditary–prostate cancer families; rather, it is likely
that the pattern of inheritance in a family (Carter et al.
1993), including the mean age at diagnosis, would be
the better discriminant. Although the autosomal reces-
sive model did not adequately fit our data, brothers of
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Table 6
Segregation Models for Probands Diagnosed at Age !60 Years
MENDELIAN MODELS ENVIRONMENTAL MODELSa
GENERAL
MODELDominant Recessive Additive Codominant
Without Generation
Effects
With Generation
Effects
Parameter:
PAA .0046 .0645 .1189 .0046 .1865* .4453 .0041
PAB .0029 .1367 .3129 .0029 .3556
† .2367 .0050
PBB .9925 .7987 .5681 .9925 .4579
‡ .3180 .9909
tAA 1.0
b 1.0b 1.0b 1.0b .1865* .2022* 1.0
tAB .5
b .5b .5b .5b .3556† .2022* .2538
tBB .0
b .0b .0b .0b .4579‡ .2022* .0
bAA 12.62 12.11 12.23 12.61 18.79 21.14 12.66
bAB 12.62 18.18 18.46 12.61 15.25 15.90 12.53
bBB 18.04 18.18 24.69 18.03 18.79 18.99 18.22
a .173 .167 .168 .173 .238 .253 .173
g 1.0 1.0 1.0 1.0 .498 .510 1.0
2n L 3,101.44 3,119.44 3,120.69 3,101.44 3,136.99 3,123.39 3,100.53
Model fit x2: .91 18.91 20.16 .91 36.46 22.86
df 4 4 4 3 3 2
P .923 .0008 .0005 .823 !.0001 !.0001
After loge
transfor-
mation:c
Model fit x2 13.34 32.61 33.52 13.07 51.42 43.79
P .010 !.0001 !.0001 .0045 !.0001 !.0001
a Within each column, parameters with the same superscript symbol (*, †, or ‡) are constrained to be equal.
b Parameter is fixed at value shown.
c Parameter estimates after loge transformation are not given.
Table 7
Segregation Models for Probands Diagnosed at Age 60–69 Years
MENDELIAN MODELS ENVIRONMENTAL MODELSa
GENERAL
MODELDominant Recessive Additive Codominant
Without Generation
Effects
With Generation
Effects
Parameter:
PAA .0026 .1918 .1919 .0026 .2308* .5473 .0779
PAB .0039 .8082 .8081 .0039 .4198
† .3111 .0923
PBB .9935 .0 .00 .9934 .3494
‡ .1417 .8297
tAA 1.0
b 1.0b 1.0b 1.0b .2308* .2412* 1.0
tAB .5
b .5b .5b .5b .4198† .2412* 1.0
tBB .0
b .0b .0b .0b .3494‡ .2412* .2089
bAA 14.12 14.69 14.69 14.09 23.96 20.98 15.92
bAB 14.12 20.81 20.79 14.12 16.74 16.34 19.81
bBB 19.76 20.81 26.89 19.75 19.84 18.22 26.28
a .194 .203 .203 .194 .244 .242 .229
g 1.0 1.0 1.0 1.0 .567 .483 1.0
2n L 8,644.14 8,671.77 8,672.12 8,644.13 8,808.69 8,752.02 8,603.44
Model fit x2: 40.70 68.33 68.68 40.69 205.25 148.58
df 4 4 4 3 3 2
P !.0001 !.0001 !.0001 !.0001 !.0001 !.0001
After loge
transfor-
mation:c
Model fit x2 29.08 65.48 65.11 28.76 203.31 148.01
P !.0001 !.0001 !.0001 !.0001 !.0001 !.0001
a Within each column, parameters with the same superscript symbol (*, †, or ‡) are constrained to be equal.
b Parameter is fixed at value shown.
c Parameter estimates after loge transformation are not given.
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Table 8
Segregation Models for Probands Diagnosed at Age x70 Years
MENDELIAN MODELS ENVIRONMENTAL MODELSa
GENERAL
MODELDominant Recessive Additive Codominant
Without Generation
Effects
With Generation
Effects
Parameter:
PAA .0017 .0570 .0343 .0019 .1689* .3699 .0023
PAB .0045 .1379 .1304 .0045 .2312
† .1451 .0159
PBB .9938 .8050 .8353 .9935 .5999
‡ .4849 .9817
tAA 1.0
b 1.0b 1.0b 1.0b .1689* .0528* 1.0
tAB .5
b .5b .5b .5b .2312† .0528* .7495
tBB .0
b .0b .0b .0b .5999‡ .0528* .0115
bAA 14.27 14.20 14.13 13.89 20.67 20.09 13.69
bAB 14.27 20.32 19.59 14.29 15.24 15.01 15.58
bBB 20.51 20.32 25.05 20.39 17.09 17.36 21.67
a .191 .192 .191 .190 .223 .232 .209
g 1.0 1.0 1.0 1.0 .404 .368 1.0
2n L 3,281.96 3,287.33 3,303.47 3,280.05 3,378.62 3,368.47 3,273.03
Model fit x2: 8.93 14.30 30.44 7.02 105.59 95.44
df 4 4 4 3 3 2
P .063 .006 !.0001 .071 !.0001 !.0001
After loge
transfor-
mation:c
Model fit x2 11.74 19.19 33.50 10.52 110.64 101.77
P .019 .0007 !.0001 .0146 !.0001 !.0001
a Within each column, parameters with the same superscript symbol (*, †, or ‡) are constrained to be equal.
b Parameter is fixed at value shown.
c Parameter estimates after loge transformation are not given.
Figure 2 Predicted cumulative risk of prostate cancer for carriers and noncarriers, based on autosomal dominant models for subsets
defined by age at diagnosis of the proband: !60, 60–69, and x70 (70) years.
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Figure 3 Cumulative risk of prostate cancer among fathers and brothers of probands who were diagnosed at age !60 years (Kaplan-
Meier estimates), and predicted risk based on the autosomal dominant–model parameters given in table 5.
Figure 4 Cumulative risk of prostate cancer among fathers and brothers of probands who were diagnosed at age 60–69 years (Kaplan-
Meier estimates), and predicted risk based on the autosomal dominant–model parameters given in table 5.
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Figure 5 Cumulative risk of prostate cancer among fathers and brothers of probands who were diagnosed at age x70 years (Kaplan-
Meier estimates), and predicted risk based on the autosomal dominant–model parameters given in table 5.
probands were at a higher risk of prostate cancer than
were fathers of probands. These results are consistent
with a recent report that found the prevalence of prostate
cancer to be greater among men who have at least one
brother affected, compared with men whose father is
affected (Monroe et al. 1995). The authors of that report
interpreted this to suggest that some prostate cancer may
be explained by an X-linked or autosomal recessive com-
ponent. However, underreporting among fathers, who,
unlike brothers, were not likely to be diagnosed by PSA,
could explain this finding. These issues, in conjunction
with a significant lack of HWE proportions, implicate
a complex genetic mechanism, with perhaps a mixture
of autosomal dominant and recessive effects, as well as
strong secular changes in the incidence of prostate cancer
that are due to improved diagnostic procedures.
There are sources of potential biases that limit gen-
eralization of our findings to all prostate cancer. First,
we selected men because they had undergone a radical
prostatectomy. To be eligible for this surgery, a man
could not have metastatic disease, nor could his general
health be poor. This ascertainment could select against
hereditary–prostate cancer families. Recent results by
Gro¨nberg et al. (1997b) suggest that men with prostate
cancer in families demonstrating linkage to the heredi-
tary prostate cancer 1 (HPC1) locus on chromosome
1q24-25 tend to have a younger age at diagnosis, higher-
grade tumors, and more-advanced disease, compared
with the general population of prostate cancer cases.
Another potential bias was that 7.6% of the nonparti-
cipants had systemic recurrence, compared with 3.6%
of the participants, suggesting that some of the nonpar-
ticipants may have had a more aggressive disease. Al-
though the quantitative implications of these potential
biases are difficult to address, we suspect that they would
weaken our power to detect Mendelian segregation of
prostate cancer. Given that the Mendelian models gave
much better fit than the environmental models, our re-
sults strongly support the existence of hereditary pros-
tate cancer, with evidence favoring autosomal dominant
segregation.
Carter et al. (1992) performed segregation analyses
similar to those that we have presented here, using sim-
ilar ascertainment—through probands receiving a radi-
cal prostatectomy for clinically localized prostate cancer
at Johns Hopkins University (JHU)—and the same meth-
ods of analysis. It is encouraging that our findings are
similar to those reported by Carter et al. (1992), albeit
only after we adjust for lack of HWE. For their auto-
somal dominant model, under HWE, the estimated sus-
ceptibility-gene frequency was .003, whereas for our
similar model (table 4) we estimated a gene frequency
of .008. Not requiring HWE, we estimated the gene
frequency as being .006. The estimated age-specific pen-
etrances for the JHU and Mayo Clinic models are pre-
sented in figure 6. The estimated penetrances for carriers
were similar, although, for noncarriers, the JHU model
tended to have a greater cumulative incidence than was
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Figure 6 Comparison of the best-fitting dominant model, assuming HWE, between the Mayo Clinic data (Mayo) and the JHU data
(Carter et al. 1992).
seen in our Mayo Clinic model. On the basis of SEER
data (Kosary et al. 1995), one would expect a higher
incidence of prostate cancer among noncarriers than
would be predicted by our model. The low estimated
lifetime penetrance among noncarriers could be due to
underreporting, many relatives not screened by PSA
(e.g., older brothers and fathers who died prior to the
widespread use of PSA screening), or a combination of
both. Although the assumption of HWE was not rea-
sonable for our data, this assumption had little impact
on the estimated cumulative-incidence curves.
The utility of our best-fitting dominant models (tables
5–8) derives from the fact that the model parameters
can be used to specify the gene frequency (.006; see table
5) and age-specific penetrance for parametric linkage
analysis. The recent report of a major prostate can-
cer–susceptibility locus on chromosome 1 (Smith et al.
1996) found a parametric two-point LOD score of 3.65
and a multipoint LOD score of 5.43, after allowance
was made for linkage heterogeneity, with linkage to
chromosome 1 in ∼34% of the families. These para-
metric analyses were based on population-based segre-
gation analyses in Swedish men (Gro¨nberg et al. 1997a).
For disease-gene mapping in families selected for early-
onset disease, the parameters in table 6, for probands
diagnosed at age !60 years, may offer a reasonable al-
ternative model for parametric linkage analyses. How-
ever, misspecification of penetrance can dramatically di-
minish the power of genetic-linkage analyses, so it may
be worthwhile to consider a few reasonable parametric
models, as well as recent model-free methods (Kruglyak
et al. 1996). We are currently scanning the genome by
genetic markers, in search of prostate cancer–sus-
ceptibility genes. Our selection of families has focused
on those with at least three living men affected with
prostate cancer, with preference for brothers and/or
cousins with an early age at onset.
Our crude analysis, comparing probands’ character-
istics versus status of family history for prostate cancer,
did not reveal any clinical/pathological features that
could be used to discriminate a genetic predisposition to
prostate cancer. A more refined analysis, correlating the
proband’s characteristics with the age at diagnosis of his
relative(s), indicated that only the proband’s age at di-
agnosis correlated with his relative’s age at diagnosis.
However, the potential ascertainment biases, discussed
above, could explain why the other clinical character-
istics of the proband did not correlate with his relative’s
age at diagnosis. It would be of interest to determine
whether pathological/clinical outcomes are correlated
among affected relatives, because this may give insight
into the biology of hereditary prostate cancer and would
offer useful clinical information. However, we did not
have pathological/clinical-outcome information on the
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relatives, so we could not perform these types of
analyses.
In summary, our results are consistent with previous
reports that carriers of a prostate cancer–susceptibility
gene have a much earlier age at onset, relative to non-
carriers. This finding is consistent with data on other
tumor-suppressor genes leading to cancer, such as the
BRCA1 gene, which increases the risk of breast cancer
(Easton et al. 1993). A potential limitation of both our
study and that of Carter et al. (1992) is that probands
were ascertained because they had undergone a radical
prostatectomy. This led to the study of (a) men in whom
the age at diagnosis was earlier than the national average
and (b) primarily localized disease. Hence, our results
may not be generalizable to all ages, although it is pro-
vocative that the subset analysis of probands diagnosed
at age x70 years indicated that the dominant model
was the best fitting. Because of the high frequency of
prostate cancer among elderly men, and because of the
complexity of hereditary prostate cancer, collaborative
efforts, such as the recently formed International Con-
sortium on Prostate Cancer Genetics (Smigel 1997), will
likely be needed to sort out the role of genetics in this
disease.
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